Skip to content

SIGA Technologies SIGA Return on equity

Return on equity at other companies

Emergent Biosolutions logo
Emergent BiosolutionsEBS
13.9%+8.1pp
Opko Health logo
Opko HealthOPK
-16.9%-21.7pp
Merck & Co. logo
Merck & Co.MRK
19%-20.3pp
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-45.6%-66.1pp
Septerna, Inc. logo
Septerna, Inc.SEPN
-12.2%
Charles River Laboratories logo
Charles River LaboratoriesCRL
-6%

Other financials

Income statement

See full
Revenue$6.2M-11.3%
Gross profit$3.3M-52.0%
Operating income-$5.3M-136%
Net income-$3.5M-746%
EPS (diluted)-$0.05-400%

Balance sheet

See full
Cash & equivalents$145.6M-10.3%
Total debt$601.0K-50.6%
Total equity$151.6M-29.8%
Total assets$219.4M-11.2%

Cash flow

See full
Operating cash flow-$8.7M-223%
CapEx--100%
Free cash flow-$8.7M-223%

Valuation

See full
Market cap$261.08M-44.3%
Enterprise value$116.11M-59.6%
P/E10.3×+3.8×
P/S2.8×+0.2×

Profitability

See full
Gross margin65.4%-11.2pp
Operating margin52.4%-7.8pp
Net margin43.2%-6.1pp
FCF margin66.2%

Returns & leverage

See full
Debt / equity0.0×
Current ratio3.2×-5.2×

Where this comes from

Calculated from SIGA Technologies’s reported figures.

Based on trailing twelve months.

The official record: SIGA Technologies’s 10-Q, filed November 6, 2025, on SEC EDGAR. View the filing →

Ask your AI about SIGA Technologies's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SIGA Technologies's return on equity?
SIGA Technologies (SIGA) reported return on equity of 39.9% in Q3 2025.
How has SIGA Technologies's return on equity changed year-over-year?
SIGA Technologies's return on equity decreased by 31.6% year-over-year, from 58.4% to 39.9%.
What is the long-term trend for SIGA Technologies's return on equity?
Over 4 years (2020 to 2024), SIGA Technologies's return on equity has grown at a -12.7% compound annual growth rate (CAGR), from 49.5% to 28.7%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.